Browsing by Author "Zur, Dinah"
Now showing 1 - 4 of 4
Results Per Page
Sort Options
- Baseline predictors for visual acuity loss during observation in diabetic macular oedema with good baseline visual acuityPublication . Busch, Catharina; Okada, Mali; Zur, Dinah; Fraser-Bell, Samantha; Rodríguez-Valdés, Patricio; Cebeci, Zafer; Lupidi, Marco; Fung, Adrian T.; Gabrielle, Pierre-Henry; Giancipoli, Ermete; Chaikitmongkol, Voraporn; Laíns, Inês; Santos, Ana Rita; Kunavisarut, Paradee; Sala-Puigdollers, Anna; Chhablani, Jay; Ozimek, Malgorzata; Hilely, Assaf; Degenhardt, Valentin; Loewenstein, Anat; Iglicki, Matias; Rehak, MatusPatients with DMO and good baseline VA, managed by observation, are of increased risk for VA loss if DRIL, HRF and EZ disruption are present at baseline. Earlier treatment with anti‐VEGF in these patients may potentially decrease the risk of VA loss at 12 months.
- Real-world outcomes of non-responding diabetic macular edema treated with continued anti-VEGF therapy versus early switch to dexamethasone implant: 2-year resultsPublication . Busch, Catharina; Fraser-Bell, Samantha; Iglicki, Matias; Lupidi, Marco; Couturier, Aude; Chaikitmongkol, Voraporn; Giancipoli, Ermete; Rodríguez-Valdés, Patricio J.; Gabrielle, Pierre-Henri; Laíns, Inês; Santos, Ana Rita; Cebeci, Zafer; Amphornphruet, Atchara; Degenhardt, Valentin; Unterlauft, Jan-Darius; Cagini, Carlo; Mané-Tauty, Valérie; Ricci, D'Amico Giuseppe; Hindi, Isaac; Agrawal, Kushal; Chhablani, Jay; Loewenstein, Anat; Zur, Dinah; Regak, MatusThe beneficial effect of an early switch to DEX implant in DME non-responders seen at month 12 was main- tained during the second year. A later switch from anti-VEGF to steroids still provided significant improvement. Eyes continued on anti-VEGF over a period of 24 months maintained vision. A quarter of eyes, which had not improved vision at 12 months, exhibited a delayed response to treatment.
- Real-world outcomes of observation and treatment in diabetic macular edema with very good visual acuity: the OBTAIN studyPublication . Busch, Catharina; Fraser-Bell, Samantha; Zur, Dinah; Rodríguez-Valdés, Patricio J.; Cebeci, Zafer; Lupidi, Marco; Fung, Adrian T.; Gabrielle, Pierre-Henry; Giancipoli, Ermete; Chaikitmongkol, Voraporn; Okada, Mali; Laíns, Inês; Santos, Ana Rita; kunavisarut, Paradee; Sala-Puigdollers, Anna; Chhablani, Jay; Ozimek, Malgorzata; Hilely, Assaf; Unterlauft, Jan Darius; Loewenstein, Anat; Iglicki, Matias; Rehak, MatusIn a real-world setting, the majority of DME patients with very good VA maintained vision at 12 months, regard- less of whether the DME was treated or not. This study supports close observation of eyes with DME and very good VA with consideration of treatment when a one line drop in vision is observed.
- Shall we stay, or shall we switch? Continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edemaPublication . Busch, Catharina; Zur, Dinah; Fraser-Bell, Samantha; Laíns, Inês; Santos, Ana Rita; Lupidi, Marco; Cagini, Carlo; Gabrielle, Pierre-Henry; Couturier, Aude; Mané-Tauty, Valérie; Giancipoli, Ermete; Ricci, Giuseppe D'Amico; Cebeci, Zafer; Rodríguez-Valdés, Patricio J.; Chaikitmongkol, Voraporn; Amphornphruet, Atchara; Hindi, Isaac; Agrawal, Kushal; Chhablani, Jay; Loewenstein, Anat; Iglicki, Matias; Rehak, MatusIn a real-world setting, eyes with DME considered refractory to anti-VEGF therapy after three monthly injections which were switched to DEX implant and had better visual and anatomical outcomes at 12 months than those that continued treatment with anti-VEGF therapy.